March 1, 2022 - Abbvie

Can CE get 340B pricing if they share claims data?

Yes – 340B ESP

Are system owned contract pharmacies exempted from this policy?

Yes (reach out to support@340besp.com to apply for the exemption)

Can CEs with no in-house pharmacy designate a contract pharmacy for 340B pricing access?

Yes

Drugs affected by this policy:

Policy currently only applies to these products:
ANDROGEL® CREON® DEPAKOTE® DUOPA® GENGRAF® HUMIRA® KALETRA® K-TAB® LUPRON® MAVYRET® NIASPAN® NIMBEX® NORVIR® ORIAHNN® ORILISSA® RINVOQ® SYNTHROID® SKYRIZI® SURVANTA® TRICOR® TRILIPIX® ULTANE® VIEKIRA PAK® ZEMPLAR® Imbruvica (effective 4/1/22)

Policy applies to what entity types?

Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.

Important FAQs/Information

Q: If my organization does not provide 340B claims data by the required date, can it elect to do so at a later date and gain access to 340B pricing for contract pharmacies? If an entity begins to supply data after February 1, 2022, it must provide data for contract pharmacy dispenses to eligible patients in the prior 45-day period. Once the required data submission has been made, AbbVie will facilitate bill to/ ship to contract pharmacy replenishment orders on product dispensed to eligible patients from and after the date of data submission as well as the prior 45-day period.

03/01/2022 – Policy Notice